GEFLIEVA 250 mg contains Gefitinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It selectively inhibits EGFR signaling, which is involved in tumor cell proliferation and survival. Gefitinib is especially effective in tumors with activating EGFR mutations.

Gefitinib is indicated for:

1. Non-Small Cell Lung Cancer (NSCLC)
   – Locally advanced or metastatic
   – With EGFR activating mutations (e.g., exon 19 deletion, L858R)

Common side effects:

•  Acneiform skin rash

•  Diarrhea

•  Dry skin, itching

•  Nausea

•  Fatigue

Serious side effects:

•  Interstitial lung disease (rare but serious)

•  Hepatotoxicity

•  Severe skin reactions

 Monitor respiratory symptoms and liver function tests regularly.

Standard adult dose:

•  250 mg once daily

 Continue treatment until disease progression or unacceptable toxicity.

NOTE: This medicine should be taken only under a doctor’s supervision.